NIH's SBIR/STTR Machine Is Fully Back On: The Four New Parent Announcements (PA-27-100/102/101, PAR-27-098), a September 5 Deadline, and What Changed

For the first time in more than a decade, NIH spent part of 2026 with no active SBIR or STTR omnibus Notices of Funding Opportunity on the books — the 2024-2 series expired without a successor while Congress worked through reauthorization. We covered that gap when it was still a source of anxiety: the June hiatus and the question of whether the September date would hold. It held. The SBIR/STTR reauthorization was signed April 13, 2026, and NIH — along with CDC and FDA — has now reissued full parent announcements. The machine is on. The application window opens August 5, 2026, and the first standard receipt date is September 5, 2026 (verify the exact date against the NOFO — when the 5th lands on a weekend or a federal holiday like Labor Day, NIH shifts to the next business day).

This is the definitive post-freeze restart, and it comes with structural changes worth understanding before you write. Here are the four announcements, what changed, and how to sequence a submission.

The four announcements

NIH consolidated the pipeline. Where there used to be four omnibus varieties — SBIR with and without clinical trials, STTR with and without clinical trials — there are now two parent solicitations, with clinical-trial status handled within each rather than by splitting into separate NOFOs. On top of those two parents sit two commercialization-focused programs. The full set:

• PA-27-100 — Parent SBIR (R43/R44): The main small-business track. Accepts Phase I, Phase II, Direct-to-Phase-II, and Fast-Track applications where the applicant company performs the majority of the research. This is where most companies will file.
• PA-27-102 — Parent STTR (R41/R42): For projects requiring formal collaboration with a university or nonprofit research institution. The PI may be employed by either the small business or the research partner — a flexibility that matters for spinouts still entangled with an academic lab.
• PA-27-101 — SBIR Phase IIB Strategic Breakthrough (R44): Congressionally mandated bridge funding for companies moving Phase II results toward commercialization. This is follow-on money beyond a completed Phase II.
• PAR-27-098 — Commercialization Readiness Pilot (SB1): Funds the un-sexy but decisive work of turning an R&D result into a market-ready product — clinical studies, IND/IDE-enabling studies, regulatory support, and manufacturing scale-up.

The consolidation is a genuine simplification. Applicants no longer have to pick the "right" of four near-identical omnibus NOFOs; you choose the parent that matches your team structure (company-led → SBIR; requires academic partner → STTR) and declare clinical-trial status inside it.

The new budget ceilings

The statutory guideline budgets for the standard tracks:

• Phase I: up to $323,090 (typically 6 months to 2 years)
• Phase II: up to $2,153,927 (1–3 years)
• Commercialization Readiness Pilot: up to $4,191,495 (up to 3 years)

Waiver topics push those ceilings higher. For qualifying research areas at specific institutes, Phase I can reach $700,000 and Phase II $3,000,000. These waivers are topic- and institute-specific — check the relevant Institute or Center's Funding Considerations page before you scope a budget, because building to the wrong ceiling is a common and avoidable way to weaken a proposal.

The Phase IIB Strategic Breakthrough (PA-27-101) is the wild card. It provides substantial follow-on funding, but the award ceilings are institute-specific and can climb well into eight figures at institutes like NCI — and, critically, the program generally requires a matching component from external funding sources (roughly dollar-for-dollar). That match requirement is the whole design: NIH is de-risking a commercialization leap that a private investor is willing to co-sign. If you can't line up the outside capital, this track isn't yet for you. Confirm the exact ceiling and match terms against the specific NOFO and your target institute, because the numbers vary more here than anywhere else in the SBIR portfolio.

Why the set-asides mean the money is real

One reason to trust that this reopening is durable, not symbolic: the SBIR/STTR set-asides are statutory percentages of each agency's extramural research budget, not discretionary line items. NIH, CDC, and FDA must allocate 3.2% of extramural funding to SBIR and 0.45% to STTR. Those percentages travel with the agency's topline. With FY2026 budgets settled and the reauthorization signed, the mandated pool refills automatically — the freeze was a paperwork gap, not a funding cut. The dollars are there; the NOFOs to capture them are now, finally, live.

How to sequence your submission

The strategic question isn't just whether to apply — it's when and into which track.

Match the announcement to your stage and structure. Company doing the majority of the work → PA-27-100 (SBIR). Project that genuinely needs a university/nonprofit partner → PA-27-102 (STTR); don't manufacture an academic collaboration just to fit STTR, but if you legitimately need one, STTR's PI flexibility is an advantage. Sitting on strong Phase II results with private capital ready to co-invest → PA-27-101 (Strategic Breakthrough). Ready to push a product across the regulatory and manufacturing finish line → PAR-27-098 (CRP).

Consider going early. Grant Engine's analysis reports that early submissions correlate with a roughly 2.4-fold increase in funding success — a figure worth treating as directional rather than gospel, but the underlying logic is sound. The September 5 cycle is the first under the reissued announcements; hitting it means the earliest possible funding start (around April 2027), better study-section assignment while product-focused reviewers still have bandwidth, and — most important — runway to resubmit in the January 5 or April 5 cycle if the first attempt misses, without blowing your whole timeline.

Write to the parts of the application that actually move scores:

• Milestone-driven, measurable aims. "Optimize the assay" is not an aim. "Achieve ≥90% sensitivity against the reference panel by month 9" is. SBIR reviewers reward specificity and a credible path.
• A commercialization pathway defined early. These are commercialization programs, not basic-science grants. Name the market, the regulatory route, the reimbursement logic, and the customer — in Phase I, not Phase II.
• Team quality alongside science. Reviewers fund teams that can execute a business, not just a hypothesis. Show the commercial competence, not only the scientific.
• Alignment with agency priorities. Map your work to the funding Institute's stated strategic priorities. A brilliant project aimed at an IC that doesn't prioritize it will struggle regardless of merit.

The bottom line

The NIH SBIR/STTR pipeline went from a genuinely alarming zero-active-NOFO gap to a fully reissued, simplified, and arguably improved structure in a single cycle. Four clean announcements have replaced a confusing four-omnibus tangle; a Strategic Breakthrough bridge and a Commercialization Readiness Pilot give strong companies real follow-on money; and the statutory set-asides guarantee the pool refills. The freeze created pent-up demand, which means the September 5, 2026 cycle will be competitive — the companies that treated the hiatus as prep time, not dead time, are the ones filing polished applications the day the window opens on August 5. If you build health, biotech, diagnostics, or medical-device technology, this is the reopening you were waiting for. Confirm the exact receipt date and budget terms in each NOFO, pick your parent, and file early. Track new SBIR/STTR openings across agencies in Granted's grant database.